Table 2.
Outcomes at 12 months of follow-up by cumulative dose
| 880 IU | 1760 IU | 2800 IU | |
|---|---|---|---|
| Systolic BP (mmHg) | 128 ± 7 | 115 ± 18 | 119 ± 18 |
| Diastolic BP (mmHg) | 78 ± 11 | 70 ± 7 | 77 ± 17 |
| Proteinuria (g/day) | 8090 ± 5571 | 3120 ± 3501 | 1505 ± 1072* |
| eGFR (mL/min) | 64 ± 16 | 78 ± 35 | 83 ± 28 |
| Albumin (mg/dL) | 2.75 ± 1.05 | 3.74 ± 0.40 | 3.95 ± 0.60** |
| Cholesterol (mg/dL) | 238 ± 17 | 163 ± 37** | 194 ± 60 |
| LDL (mg/dL) | 125 ± 31 | 80 ± 31 | 91 ± 43 |
| HDL (mg/dL) | 75 ± 14 | 53 ± 24 | 56 ± 25 |
| TG (mg/dL) | 190 ± 92 | 147 ± 79 | 234 ± 159 |
*P < 0.05 for trend across groups.
**P < 0.05 versus 880 IU.